by curtis@digitalliance.com | Jan 18, 2018 | Blog
Bioethics International recently published their second, long-promised Good Pharma Scorecard, a ranking of large biopharmaceutical companies’ compliance with disclosing data for new medicines to public registries, in BMJ Open. With this recent publication, a spotlight...
by curtis@digitalliance.com | Nov 15, 2017 | News
MMS Holdings Inc. (MMS) announced today that it was selected by Paratek Pharmaceuticals, Inc., (NASDAQ: PRTK) to support the development of its U.S. new drug applications (NDAs) for omadacycline. Paratek is a biopharmaceutical company focused on the development and...
by curtis@digitalliance.com | Nov 2, 2017 | News
MMS is collaborating with the DIA for an upcoming complimentary webinar, “Optimizing the Use of Clinical Trial Disclosure Systems to Meet Complex and Evolving Global Regulatory Requirements.” Learning Objectives Determine key drivers for the use of technology to...
by curtis@digitalliance.com | Sep 26, 2017 | News
Pfizer has selected MMS Holdings Inc. (MMS), headquartered in Canton, MI, as a preferred provider for support writing plain language summaries of the results for all its Phase 2 and 3 clinical trials. In advance of implementation of EU Clinical Trial Regulation No....
by curtis@digitalliance.com | Jun 27, 2017 | Blog
In the United States, the number of patients with Alzheimer’s disease is projected to increase from the current prevalence of around 5.5 million to around 14 million in 2050. These sobering numbers reflect an urgent need for increased awareness and proactive decision...
